Francis Medical

Francis Medical is an innovative medical device company pioneering water vapor ablation therapy for prostate cancer. Its core technology, the Vanquish System, delivers sterile water vapor to ablate targeted prostate tissue with the aim of being effective while minimizing damage to surrounding structures and reducing side effects like incontinence and erectile dysfunction. The company is currently generating clinical evidence through its VAPOR 2 multi-center pivotal study to support the system's use in managing localized, intermediate-risk prostate cancer. As a private firm, it is in the commercial stage for its device as an ablation tool but is still seeking broader therapeutic claims from the FDA.

Proprietary water vapor ablation platform that uses the latent heat of vaporization to deliver thermal energy directly to cell membranes for precise tissue ablation.

Francis Medical competes in the focal therapy for prostate cancer market against established technologies like High-Intensity Focused Ultrasound (HIFU), cryoablation, and laser ablation. Its key differentiator is the novel water vapor energy modality, which aims to offer precise ablation with potentially better preservation of urinary and sexual function.